代谢与减重手术在子宫内膜上皮内瘤变及子宫内膜癌肥胖管理中的作用
本临床实践声明由妇科肿瘤学会(SGO)与美国胃肠内镜外科医师学会(SAGES)联合制定,综合文献评估代谢与减重手术(MBS)及其他减重干预在子宫内膜上皮内瘤变(EIN)和子宫内膜癌(EC)患者肥胖管理中的作用。声明指出MBS是最有效且持久的肥胖治疗方式,可能降低癌症风险并改善整体健康结局,强调早期多学科评估并将肥胖治疗整合至肿瘤诊疗中。
要点
- 肥胖是EC可干预的重要危险因素,与更差的肿瘤学及总体结局相关。
- MBS可产生显著且持久的减重效果,改善肥胖相关合并症并降低激素相关癌症风险。
- 早期多学科评估并将肥胖治疗整合至肿瘤诊疗中有助于优化患者结局。
核心结论
- MBS是EIN和EC女性肥胖最有效且持久的治疗方式,可能降低癌症风险并改善整体健康结局。
研究设计与样本
- 本临床实践声明由SGO与SAGES合作制定,综合当前关于肥胖、EC结局及减重干预的文献。
主要发现
- 肥胖是EC主要可干预危险因素,与更差肿瘤学及总体结局相关,心血管疾病是该人群首位死因。
- 生活方式和药物干预可实现适度减重,但常受可持续性限制。
- MBS产生显著且持久减重,改善肥胖相关合并症,并与激素相关癌症(包括EC)风险降低相关。
- 新兴证据支持在癌症诊疗各时间点整合MBS的可行性,包括作为确定性手术的桥接或保守治疗的辅助。
- 早期减重有助于改善手术候选资格和代谢健康。
临床怎么用
- 对EIN和EC合并肥胖的女性,应早期进行多学科评估。
- 将肥胖治疗整合至肿瘤诊疗中,以优化患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide evidence-based guidance on the role of metabolic and bariatric surgery (MBS) and other weight loss interventions in the management of obesity among women with endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC). METHODS: This clinical practice statement, developed collaboratively by the Society of Gynecologic Oncology (SGO) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), synthesizes current literature on obesity, EC outcomes, and weight loss interventions, including lifestyle modification, anti-obesity medications, endoscopic bariatric therapies, and MBS. RESULTS: Obesity is a major modifiable risk factor for EC and is associated with worse oncologic and overall outcomes, with cardiovascular disease representing the leading cause of mortality in this population. Lifestyle and pharmacologic interventions can achieve modest weight loss but are often limited by sustainability. In contrast, MBS produces substantial and durable weight loss, improves obesity-related comorbidities, and is associated with reduced risk of hormone-related cancers, including EC. Emerging evidence supports the feasibility of incorporating MBS at various time points in cancer care, including as a bridge to definitive surgery or as an adjunct to conservative management, with early weight loss contributing to improved surgical candidacy and metabolic health. CONCLUSIONS: MBS represents the most effective and durable treatment for obesity in women with EIN and EC and may reduce cancer risk and improve overall health outcomes. Early multidisciplinary evaluation and integration of obesity treatment into oncologic care are essential to optimize patient outcomes.
引用
- Harrington S, El Ghazal N, Tung C, et al. The role of metabolic and bariatric surgery for obesity management in endometrial intraepithelial neoplasia and endometrial cancer: A Society of Gynecologic Oncology and Society of American Gastrointestinal and Endoscopic Surgeons clinical practice statement. Gynecol Oncol. 2026. PMID: 42579945. doi:10.1016/j.ygyno.2026.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。